CORT250117C24000
- 0.00
- 0.000.00%
Corcept Therapeutics Newsroom
Here's Why Corcept Therapeutics (NASDAQ:CORT) Has Caught The Eye Of Investors
Sector Update: Health Care Stocks Flat to Higher Premarket Tuesday
Corcept Therapeutics Files New Drug Application for Relacorilant
Corcept Therapeutics Submits New Drug Application To FDA For Its Proprietary, Selective Cortisol Modulator, Relacorilant, To Treat Patients With Cushing's Syndrome
Express News | Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism
Will Corcept Therapeutics Incorporated (CORT) Make You Rich In 2025?
Corcept Therapeutics Presents Phase 3 Long-Term Extension Study Of Relacorilant Demonstrated Durable Cardiometabolic Improvements In Patients With Hypercortisolism
Express News | Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients With Hypercortisolism
Truist Financial Maintains Corcept Therapeutics(CORT.US) With Buy Rating
Corcept Therapeutics (CORT) Receives a Buy From Truist Financial
Corcept Announces Primary Endpoint Met In Treatment Phase Of CATALYST Trial In Patients With Hypercortisolism And Difficult-To-Control Diabetes
Express News | Corcept Therapeutics Inc - Korlym Safety Profile Consistent With Label, No New Side Effects
Express News | Corcept Announces Positive Results in Treatment Phase of Catalyst Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday
Optimistic Outlook for Corcept Therapeutics Amid Promising Developments and Regulatory Advantages
Correction to Corcept Therapeutics Shares Fall Article
Corcept Therapeutics Fall 7% After ALS Drug Fails Trial
Express News | Corcept Therapeutics Inc - Dazucorilant Patients Experienced More Gastrointestinal Upset Than Placebo
Corcept Announces Results From Phase 2 Study Of Dazucorilant In Patients With Amyotrophic Lateral Sclerosis; DAZALS Did Not Meet Its Primary Endpoint, Which Was The Change From Baseline In The ALS Functional Rating Scale-Revised In Patients Who...